Dose-Response Association of CD8( ) Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Ellen L Goode; Matthew S Block; Kimberly R Kalli; Robert A Vierkant; Wenqian Chen; Zachary C Fogarty; Aleksandra Gentry-Maharaj; Aleksandra Toloczko; Alexander Hein; Aliecia L Bouligny; Allan Jensen; Ana Osorio; Andreas D Hartkopf; Andy Ryan; Anita Chudecka-Glaz; Anthony M Magliocco; Arndt Hartmann; Audrey Y Jung; Bo Gao; Brenda Y Hernandez; Brooke L Fridley; Bryan M McCauley; Catherine J Kennedy; Chen Wang; Chloe Karpinskyj; Christiani B de Sousa; Daniel G Tiezzi; David L Wachter; Esther Herpel; Florin Andrei Taran; Francesmary Modugno; Gregg Nelson; Jan Lubinski; Janusz Menkiszak; Jennifer Alsop; Jenny Lester; Jesus Garcia-Donas; Jill Nation; Jillian Hung; Jose Palacios; Joseph H Rothstein; Joseph L Kelley; Jurandyr M de Andrade; Luis Robles-Diaz; Maria P Intermaggio; Martin Widschwendter; Matthias W Beckmann; Matthias Ruebner; Mercedes Jimenez-Linan; Naveena Singh; Oleg Oszurek; Paul R Harnett; Peter F Rambau; Peter Sinn; Philipp Wagner; Prafull Ghatage; Raghwa Sharma; Robert P Edwards; Roberta B Ness; Sandra Orsulic; Sara Y Brucker; Sharon E Johnatty; Teri A Longacre; Ursula Eilber; Valerie McGuire; Weiva Sieh; Yanina Natanzon; Zheng Li; Alice S Whittemore; Anna deFazio; Annette Staebler; Beth Y Karlan; Blake Gilks; David D Bowtell; Estrid Hogdall; Francisco J Candido dos Reis; Helen Steed; Ian G Campbell; Jacek Gronwald; Javier Benitez; Jennifer M Koziak; Jenny Chang-Claude; Kirsten B Moysich; Linda E Kelemen; Linda S Cook; Marc T Goodman; Maria Jose Garcia; Peter A Fasching; Stefan Kommoss; Suha Deen; Susanne K Kjaer; Usha Menon; James D Brenton; Paul DP Pharoah; Georgia Chenevix-Trench; David G Huntsman; Stacey J Winham; Martin Kobel; Susan J Ramus

Journal article

Dose-Response Association of CD8( ) Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Ellen L Goode, Matthew S Block, Kimberly R Kalli, Robert A Vierkant, Wenqian Chen, Zachary C Fogarty, Aleksandra Gentry-Maharaj, Aleksandra Toloczko, Alexander Hein, Aliecia L Bouligny, Allan Jensen, Ana Osorio, Andreas D Hartkopf, Andy Ryan, Anita Chudecka-Glaz, Anthony M Magliocco, Arndt Hartmann, Audrey Y Jung, Bo Gao, Brenda Y Hernandez Show all

JAMA ONCOLOGY | AMER MEDICAL ASSOC | Published : 2017

DOI: 10.1001/jamaoncol.2017.3290

Abstract

Importance: Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. Objective: To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. Design, Setting, and Participants: This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years. Exposures: Following immunohistochemical analysis, CD8+ TILs were..

View full abstract

University of Melbourne Researchers

David Bowtell Author The Sir Peter Maccallum Department of Oncology

Ian Campbell Author The Sir Peter Maccallum Department of Oncology

Related Projects (5)

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

Australian Biospecimen Network-Oncology

Availability of ethically consented, clinically annotated human cancer tissue is a key determinant of the international competitiveness of A..

AUSTRALASIAN BIOSPECIMEN NETWORK-ONCOLOGY

nan

Molecular Epidemiology of Ovarian Research Institute

Grants

Awarded by Canadian Institutes for Health Research

Awarded by Brazilian National Council for Scientific and Technological Development

Awarded by Calgary Laboratory Services Internal Research Competition

Awarded by German Federal Ministry of Education and Research of Germany

Awarded by US National Cancer Institute

Awarded by National Institutes of Health/National Center for Research Resources/General Clinical Research Center

Awarded by US Army Medical Research and Materiel Command

Awarded by NIH

Awarded by Cancer Research UK

Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by National Health and Medical Research Council Enabling

Awarded by Cancer Institute NSW

Awarded by National Cancer Institute, Bethesda, Maryland

Awarded by Danish Cancer Society, Copenhagen, Denmark

Awarded by American Cancer Society Early Detection Professorship

Awarded by National Center for Advancing Translational Sciences (NCATS)

Awarded by The Francis Crick Institute

Awarded by Gynaecology Research Fund (The Eve Appeal)

Awarded by NATIONAL CANCER INSTITUTE

Awarded by NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES

Funding Acknowledgements

Funding was provided by Canadian Institutes for Health Research (MOP 86727); Brazilian National Council for Scientific and Technological Development, grant No. 478416/2009-1; Calgary Laboratory Services Internal Research Competition RS10-533; German Federal Ministry of Education and Research of Germany (01 GB 9401); German Cancer Research Center (DIKFZ); US National Cancer Institute K07-CA80668, P50-CA159981, R01CA095023; National Institutes of Health/National Center for Research Resources/General Clinical Research Center grant M01-RR000056; US Army Medical Research and Materiel Command DAMD17-02-1-0669; NIH (R01-CA122443, P50-CA136393, P30-CA15083, U01-CA71966, U01-CA69417, R01-CA16056, K07-CA143047); Cancer Research UK (C490/A10119, C490/A10123, 6490/A16561); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge and at University College Hospital, "Women's Health Theme"; NIH SIB 685; the Eve Appeal; the Oak Foundation; and Deutsche Forschungsgemeinschaft. The Australian Ovarian Cancer Study Group was supported by the US Army Medical Research and Materiel Command under DAMD17-01-1-0729; The Cancer Council Victoria; Queensland Cancer Fund; The Cancer Council, New South Wales,; the Tom Baker Cancer Centre Translational Laboratories; The Cancer Council, South Australia; The Cancer Foundation of Western Australia; The Cancer Council Tasmania; and the National Health and Medical Research Council of Australia (NHMRC; 10400413, 10400281). The AOCS gratefully acknowledges additional support from the Peter MacCallum Cancer Foundation and Ovarian Cancer Australia (OCA). The Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group, was funded by the National Health and Medical Research Council Enabling grants ID 310670 and ID 628903 and the Cancer Institute NSW grants 12/RIG/1-17 and 15/RIG/116. Funding for MALOVA was provided by research grant R01-CA61107 from the National Cancer Institute, Bethesda, Maryland; research grant 9422252 from the Danish Cancer Society, Copenhagen, Denmark; and the Mermaid I project. Drs DeFazio and Harnett are funded by Cancer Institute NSWgrant 15/TRC/1-01. Dr Karlan is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), grant UL1TR000124.